Proactive case-finding and risk-stratification in people at risk of chronic liver disease in Greater Manchester: a cost-effectiveness analysis
Rogers, G.; Landi, S.; Purssell, H.; Momoh, T.; Yates, S.; Street, O.; Piper Hanley, K.; Hanley, N.; Athwal, V.; Payne, K.
Show abstract
ABSTRACTO_ST_ABSBackgroundC_ST_ABSWe urgently need innovative strategies to combat a growing epidemic of chronic liver disease (CLD). ID-LIVER was a collaborative project aiming to improve detection of reversible-stage CLD in a region with high prevalence of critical risk factors. ObjectiveTo determine the cost-effectiveness of ways to identify people with significant CLD, including proactive case-finding in the community (supplementing reactive referrals from primary care) and/or risk-stratification (using FIB-4 or ID-LIVER-ML -- a novel machine-learning risk-stratification tool). DesignState-transition decision-analytic model estimating lifetime healthcare costs (2023/24 GBP) and quality-adjusted life-years (QALYs) associated with six alternative strategies for case-finding and risk-stratification. We simulated cohorts of people with alcohol-related liver disease (ARLD) and metabolic dysfunction-associated steatotic liver disease (MASLD). We populated the model with data collected in ID-LIVER, supplemented by parameters from literature and routine data-sources. We estimated incremental cost-effectiveness and performed deterministic and probabilistic sensitivity analyses. ResultsAny case-identification strategy costing [≤]3,300 GBP per person with significant CLD identified would meet English cost-effectiveness thresholds (20,000 GBP/QALY). In our decision-set, the cheapest strategy is to use FIB-4 in the reactive-only population. ID-LIVER-ML generates more population health at reasonable cost (10,490 GBP/QALY gained). Introducing proactive case-finding generates further health benefits, costing 12,952 GBP/QALY gained. Using ID-LIVER-ML in the proactive-and-reactive population has the highest probability of maximising cost-effectiveness, when valuing QALYs at 20,000 GBP. ConclusionSmart methods of case-finding and risk-stratification identify people with significant CLD in the community, and are likely to represent good value for money in England.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.